Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001415889-12-000381
Filing Date
2012-03-16
Accepted
2012-03-16 17:03:40
Documents
10
Period of Report
2011-12-31

Document Format Files

Seq Description Document Type Size
1 FLUOROPHARMA 10-K DEC 31 2011 fpmi10k-dec312011.htm 10-K 1625875
2 CODE OF ETHICS ex14.htm EX-14 45984
3 CERT OF THE CEO AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECT 302 OF THE SARB ex31-1.htm EX-31.1 12183
4 CERT OF THE CEO AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 13 ex32-1.htm EX-32.1 6705
  Complete submission text file 0001415889-12-000381.txt   3655672

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA fpmi-20111231.xsd EX-101.SCH 29840
6 XBRL TAXONOMY CALCULATION LINKBASE fpmi-20111231_cal.xml EX-101.CAL 32656
7 XBRL TAXONOMY DEFINITION LINKBASE fpmi-20111231_def.xml EX-101.DEF 31267
8 XBRL TAXONOMY LABEL LINKBASE fpmi-20111231_lab.xml EX-101.LAB 170582
9 XBRL TAXONOMY PRESENTATION LINKBASE fpmi-20111231_pre.xml EX-101.PRE 96294
10 XBRL INSTANCE DOCUMENT fpmi-20111231.xml EX-101.INS 345317
Mailing Address 500 BOYLSTON STREET SUITE 1600 BOSTON MA 02116
Business Address 500 BOYLSTON STREET SUITE 1600 BOSTON MA 02116 (617) 482-2333 X122
FLUOROPHARMA MEDICAL, INC. (Filer) CIK: 0001402785 (see all company filings)

EIN.: 208325616 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 333-147193 | Film No.: 12698399
SIC: 2835 In Vitro & In Vivo Diagnostic Substances